Keyphrases
O-polysaccharide
100%
Lipopolysaccharide
100%
Shigella
100%
Shigella Vaccine
100%
Protein Conjugates
100%
Vaccine Development
100%
Emerging Approaches
100%
Shigella Sonnei
66%
Shigella Flexneri
50%
IgG Antibody
50%
Glycoconjugates
50%
Israeli
16%
Healthy Volunteers
16%
Advanced Stage
16%
Older Adults
16%
Young children
16%
Clinical Evaluation
16%
Soldiers
16%
Low Risk
16%
Field Unit
16%
Serum IgG
16%
Conjugate Vaccine
16%
S. Dysenteriae
16%
Most Common Cause
16%
Diarrheal Disease
16%
Infection Risk
16%
Covalently Bound
16%
Protective Efficacy
16%
Vaccine Strain
16%
Low-middle Income Countries
16%
Disease-associated
16%
Correlates of Protection
16%
Successful Development
16%
Phase II Study
16%
Moderate-to-severe Diarrhea
16%
Haemophilus Influenzae Type b Vaccine
16%
Young Ones
16%
Phase I Study
16%
Attenuated Oral Vaccine
16%
Parenteral Delivery
16%
Local Immune Response
16%
Protein Carrier
16%
U.S. National Institutes of Health
16%
Gut mucosa
16%
Mandatory Vaccines
16%
Protective Immunity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Lipopolysaccharide
100%
Polysaccharide
100%
Shigella
100%
Shigella Vaccine
100%
Vaccine Development
100%
Immunoglobulin G
50%
Glycoconjugate
50%
Infection
33%
Conjugate Vaccine
33%
Diseases
33%
Normal Human
16%
Clinical Trial
16%
Diarrhea
16%
Dysentery
16%
Haemophilus Influenzae Type B
16%
Vaccine Strain
16%
Oral Vaccine
16%